Xarelto's Efficacy Impresses In ACS, But Bleeding Risk Will Complicate Approval

Bayer/Johnson & Johnson's rivaroxaban demonstrated a significant reduction in the risk of major adverse cardiovascular events, but it also significantly increased the risk of major bleeding in the Phase III ATLAS trial of acute coronary syndrome patients.